Therapeutic use of a growth factor, METRNL
US10034918B2 · kind B2 · utility
0Cited by
4References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 8, 2017 |
| Grant date | Jul 31, 2018 |
| Priority date | — |
| Expiry date | May 8, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2300/414
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.